Gastrointestinal Cancer

Certain patients whose cancer cells form mutations and build up a resistance to drugs, drive the need for second- and third-line therapies

Oncolytic viruses have the potential of killing cancer stem cells, particularly in cases of potentially fatal pancreatic cancer

Afinitor is now approved for the treatment of pancreatic neuroendocrine tumors in patients with unresectable, locally advanced, or metastatic disease

New data suggest that individuals who drink moderate amounts of alcohol have an increased likelihood of developing colorectal cancer

Spectrum Pharmaceuticals stock prices are the biggest story across the internet, not the FDA's approval of Fusilev

Aflibercept, an investigational angiogenesis inhibitor, improved overall survival as a second-line treatment for patients with mCRC

A class of drugs that has shown encouraging results in breast and ovarian cancers with BRCA gene mutations may also benefit patients who have colorectal cancers

Pfizer's sunitinib provides a favorable benefit-risk profile in patients with unresectable pancreatic neuroendocrine tumors (pNETs)

After much anticipation the Oncologic Drugs Advisory Committee has returned a verdict on Novartis' everolimus (Afinitor)

In 1993, William G. Cance, MD, was the first researcher to clone human focal adhesion kinase (FAK) and demonstrate its overexpression in metastatic cancers.

In this review article, the author discusses the use of tyrosine kinase inhibitors in the management of patients with gastrointestinal stromal tumors.

The results of a systematic review and meta-analysis suggest that the mortality risk for colon cancer patients begins to increase with any avoidable delay in adjuvant chemotherapy beyond 4 weeks.

Data from a large randomized trial showed that treatment with the targeted agent everolimus was associated with a 65% improvement in progression-free survival (PFS) in patients with advanced pancreatic neuroendocrine tumors (PNETs).

Laura Metcalfe, MSN, RN, APN, C, AOCNS Advanced Practice Nurse, GI Division from John Theurer Cancer Center on Colorectal Screening

Laura Metcalfe, MSN, RN, APN, C, AOCNS Advanced Practice Nurse, GI Division from John Theurer Cancer Center on the Virtual Colonoscopy

Useful Online Resources and Clinical Trials for Renal Cell Carcinoma

The University of Glasgow will begin offering medical and scientific research findings, including cancer-related discoveries, to businesses and entrepreneurs free of charge

The FDA has given Merit Medical Systems the green light for a phase III clinical trial investigating QuadraSphere Microspheres in patients with primary liver cancer.

The FDA has notified Spectrum Pharmaceuticals that it will decide whether to approve Fusilev (levoleucovorin) for colorectal cancer within 6 months.

Useful Online Resources and Clinical Trials for Colon Cancer

Useful Online Resources and Clinical Trials for Liver Cancer

Useful Online Resources and Clinical Trials for Gastrointestinal Cancers

ColoPrint, a microarray-based gene signature test, accurately identifi ed the risk of recurrence of colorectal cancer in patients with localized stage II disease, raising the potential of an exciting new prognostic tool for clinicians.

The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey, one of the largest cancer centers in the United States

Siddhartha Mukherjee, MD, discusses his book The Emperor of All Maladies.